Will Immunotherapy Move Into All Lung Cancer Patient Populations? – Curetoday.com
|
Will Immunotherapy Move Into All Lung Cancer Patient Populations?
Curetoday.com The efficacy of single-agent immunotherapy in NSCLC has been showcased, most recently with the five-year follow-up results of the CA209-003 trial at the 2017 AACR Annual Meeting. Here, it was demonstrated that treatment with the PD-1 inhibitor Opdivo … |
